MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Beneficial and Protective Effects of Withania Someniferais On Mice Brain: A Therapeutic Potential Drug for Parkinson’s Disease

S. Rajput, S. Sinha (New Delhi, India)

Meeting: 2017 International Congress

Abstract Number: 563

Keywords: Aging, Catalase, Parkinsonism

Session Information

Date: Tuesday, June 6, 2017

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: Objective of our study was evaluate effect of  Withania Someniferais leaves on Parkinsons brain of mice 

Background: Parkinson’s disease (PD), an age-related disorder, is accompanied by the symptoms, tremor, bradykinesia, rigidity, stooped posture and instability. The disease progresses slowly and may ultimately produce complete akinesia. The neuropathology of the disease is based on the depigmentation and cell loss in the dopaminergic nigrostriatal tract of the brain with the corresponding decrease in the striatal dopamine concentration and the presence of eosinophilic inclusions called Lewy bodies. Withania Someniferais (WS)  retard brain aging and help in regeneration of neural tissues besides producing antistress, adaptogenic and memory enhancing effect.  

Methods: In present study  6-hydroxydopamine (6-OHDA) model of PD mice were used. The symptoms of PD such as tremors, akinesia, rigidity, catalepsy, and vacuous chewing movements (VCMs) were evaluated. The methanolic extract of WS was administered at doses of 200 mg and 500 mg/kg body weight followed by stress. The combination of L-dopa and carbidopa was used as a standard drug. Behavioral studies such as locomotor activity and grip strength were determined, and oxidative stress was evaluated in mice brain.  ANOVA was used followed by post hoc Turkey test.

Results: Brain was used for biochemical and histopathological study. Animal exposed to stress showed significant decrease in Superoxide dismutase (SOD), Catalase (CAT), Glutathione (GSH) and total protein. This was accompanied by simultaneous increase in Thiobarbituric acid reactive substances – TBARS  evel. Treatment with Withania Somenifera had no significant but moderate effect on antioxidant enzyme (SOD and CAT). Pretreatment with WS (200 and 500 mg/kg) significantly reduced the intensity of muscular rigidity, duration of catalepsy, akinesia, the number of tremors, and increase fighting behavior. The locomotor activity and grip strength were significantly increased by WS.  Treatment with WS significantly reduced LPO level and restored the defensive antioxidant enzymes SOD and CAT in mice brain.

Conclusions: Present study provides evidences that oral administration of  alcoholic extract of WS leaves have shown anti-aging effect in stress.

To cite this abstract in AMA style:

S. Rajput, S. Sinha. Beneficial and Protective Effects of Withania Someniferais On Mice Brain: A Therapeutic Potential Drug for Parkinson’s Disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/beneficial-and-protective-effects-of-withania-someniferais-on-mice-brain-a-therapeutic-potential-drug-for-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/beneficial-and-protective-effects-of-withania-someniferais-on-mice-brain-a-therapeutic-potential-drug-for-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley